Conotoxins
conopeptides; by family — α-conotoxins (e.g. Vc1.1/ACV1, GID, ImI), μ-conotoxins (e.g. GIIIA, SIIIA, KIIIA), χ-conotoxin MrIA (Xen2174), δ-, κ- and ω-conotoxins. Ziconotide (ω-MVIIA) has its own profile (#134)
1What it is
Cone snails are predatory marine molluscs that harpoon fish, worms or other snails with a hollow radular tooth and inject a venom containing dozens to hundreds of short peptides. Each species makes its own cocktail; across the roughly 700 Conus species the total number of distinct conopeptides is estimated in the hundreds of thousands, of which a few hundred have been characterised. Baldomero Olivera's laboratory at the University of Utah established the field from the 1970s onward.
What makes conotoxins scientifically valuable is subtype selectivity. Where a classical drug might hit a whole receptor family, individual conotoxins discriminate between closely related subtypes — a particular nicotinic receptor stoichiometry, a particular sodium channel isoform. That precision made them the reagents with which much of ion channel pharmacology was mapped.
One has become a medicine. Ziconotide, the synthetic form of ω-conotoxin MVIIA from Conus magus, is approved for severe chronic pain delivered by implanted intrathecal pump, and is covered in profile #134. This page covers the rest of the class, where the honest summary is: extraordinary pharmacological tools, two serious but unsuccessful clinical attempts, and a great deal of preclinical work.
2How it's thought to work
Different families, genuinely different mechanisms:
3What the research shows
Vc1.1 / ACV1 for neuropathic pain
Xen2174 (χ-conotoxin MrIA analogue)
μ-conotoxins as research tools
Other families and indications
Human exposure — the sting
4Reported side effects and interactions
Literature-reported
Literature (clinical). the most informative safety data in the class comes from ziconotide (#134), where intrathecal administration causes dizziness, nausea, confusion, memory impairment, nystagmus, gait disturbance and — importantly — serious psychiatric and neurological adverse effects including psychosis and suicidality, with a narrow therapeutic window requiring slow titration. Any conotoxin acting centrally should be assumed to carry route-specific neurological risk until shown otherwise.
Literature (envenomation). paresthesia, local numbness, muscle weakness, diplopia, dysphagia, flaccid paralysis and respiratory arrest. Severity relates to species and sting site.
Community-reported
Community use: essentially none documented. Self-administration would be dangerous and futile — the one member of the class with proven analgesic efficacy requires a surgically implanted intrathecal pump and physician-managed titration because of its narrow window, and the paralytic families have no therapeutic effect at all, only toxicity.Theoretical. for μ-conotoxins, systemic sodium channel blockade means cardiac and skeletal muscle toxicity; for α-conotoxins at the muscle subtype, neuromuscular paralysis; for any of them, immunogenicity on repeat dosing.
Interactions. for ziconotide, additive central nervous system depression with opioids and sedatives. Not characterised for other members.
Markers researchers commonly monitor
No compound-specific markers are established for the unapproved members, and no human administration occurs outside trials. For context: No laboratory markers apply to research use.
| Marker | Why it's watched |
|---|---|
| For intrathecal ziconotide (#134), the established clinical monitoring is neurological and psychiatric | serum creatine kinase is also followed, as elevations have been reported — and that profile is the only clinically validated monitoring framework in the class. |
| Electrophysiological target engagement (patch-clamp block of the specific channel subtype) is the measure used in preclinical work | |
| In envenomation, the relevant monitoring is respiratory | oxygen saturation, ventilatory adequacy, bulbar function — because death is from paralysis, not from a measurable biochemical derangement. |
Free for everyone. Safety information is never behind a paywall.
5Research context and safety notes
Conotoxins are among the most valuable reagents in ion channel pharmacology, and that is what they are: - Potency scale. Many of these peptides act at nanomolar or sub-nanomolar concentrations, and the paralytic families have lethal doses in small animals far below the quantities handled routinely in a laboratory. Precision of handling is a safety requirement, not a nicety. - Route is the whole problem. Peptides of this size do not cross the blood–brain barrier and are cleared rapidly. The only conotoxin that reached the clinic did so by intrathecal pump, and that route is the source of both its efficacy and its adverse effects. Nothing about systemic or administration is supported for any member of the class. - Species differences are not theoretical. The Vc1.1 programme failed because rat and human receptor potencies differ by orders of magnitude. Animal efficacy data for this class should be read with that case in mind. - Source. Research peptides are chemically synthesised, with oxidative folding to form the correct disulfide pattern — a non-trivial step, and the reason that material of uncertain provenance is of uncertain identity. Live cone snails are hazardous animals. No preparation, solvent, concentration or storage guidance is given here.
6Commonly studied alongside
Ziconotide (#134) as the one approved member of the class; tetrodotoxin and saxitoxin as comparator sodium channel blockers; ProTx-II (#199) as a spider-venom sodium channel peptide aimed at the same Nav1.7 target; mambalgins (#193) as a parallel venom-derived analgesic effort.
Informational cross-links. Not stack recommendations.
7Regulatory status by region
| Region | Status (checked —) |
|---|---|
| United States | Ziconotide (#134) is FDA-approved. No other conotoxin is approved; research chemicals only |
| European Union | Ziconotide authorised; no others |
| United Kingdom | Ziconotide licensed; no others |
| Australia | Ziconotide approved; no others. (Noted because much of the foundational work and the Vc1.1 programme were Australian) |
| South Africa | Ziconotide status uncertain †; no other conotoxin registered |
| Sport | Not listed by WADA as a class; S0 would apply in principle to non-approved substances. No performance application |
8Open questions
- Can subtype selectivity be retained in a molecule small or stable enough to be given systemically or orally?
- Was the α9α10 nicotinic receptor the wrong target, or Vc1.1 the wrong molecule, or both — and does the GABA-B mechanism offer a better route?
- How many of the estimated hundreds of thousands of conopeptides are pharmacologically novel, and does the field have the throughput to find out?
- Why does a drug with ziconotide's efficacy remain so little used in practice — and what does that say about the viability of intrathecal peptides generally?
9References
- 1Terlau H, Olivera BM (2004). Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol Rev. PubMed · DOI
- 2Olivera BM et al. (1985). Peptide neurotoxins from fish-hunting cone snails. Science. PubMed · DOI
- 3Satkunanathan N et al. (2005). Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones. Brain Res. PubMed · DOI
- 4Callaghan B et al. (2008). Analgesic alpha-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABA-B receptor activation. J Neurosci. PubMed · DOI
- 5Nielsen CK et al. (2005). Anti-allodynic efficacy of the chi-conopeptide, Xen2174, in rats with neuropathic pain. Pain. PubMed · DOI
- 6Safavi-Hemami H et al. (2015). Specialized insulin is used for chemical warfare by fish-hunting cone snails. PNAS. PubMed · DOI
- 7Lewis RJ, Dutertre S, Vetter I, Christie MJ (2012). Conus venom peptide pharmacology. Pharmacol Rev. PubMed · DOI
† Being confirmed by our reviewers against current sources.
10Community
Threads and protocols are visible to members. Joining is free.
Self-reported side effects Phase 2
11Page history
Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.